A Overview Of Type And New Emerging Preventive Measures Of Mammary Carcinoma

Mammary carcinoma

  • Anusha Jasmin R J
  • Ramalingam Kothai
  • Balasubramanian Arul
Keywords: life-threatening, tumours, lumps, milk-producing lobules, Metastasis

Abstract

The illness known as breast cancer is caused by aberrant breast cells that proliferate and develop into tumors. Worldwide, breast cancer affects people in every nation. Globally, breast cancer claimed 670 000 lives. Women without any particular risk factors other than age and sex account for almost half of all cases of breast cancer. In 157 nations, breast cancer was the most frequent cancer among women. Men are affected by breast cancer in a range of 0.5–1%. Tumours have the potential to grow throughout the body and become lethal if ignored. Inside the breast's milk ducts or milk-producing lobules are where breast cancer cells first proliferate. The earliest form is detectable in its early stages and is not life-threatening. Nearby breast tissue can become infected with cancerous cells. Tumors produced by this result in thickening or lumps. Cancers that are invasive can spread to adjacent lymph nodes or other organs. Metastasis can be lethal and perhaps fatal. Treatment is determined by the patient and the cancer's type, and its extent of dissemination. Medication, radiation therapy, and surgery are all used in treatment and life style change to reduce the risk of mammay carcinoma.

Author Biographies

Anusha Jasmin R J

Research Scholar, Vinayaka Mission’s Rsesarch Foundation, Salem.

Ramalingam Kothai

Professor, Department of Pharmacology, Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation (Deemed to be University), Salem-636008, Tamilnadu, India

Balasubramanian Arul

Professor, Department of Pharmacology, Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation (Deemed to be University), Salem-636008, Tamilnadu, India

References

Charles V. Clevenger,Priacilla A. Furth, Susan E. Hankinson, Linda A. Schuler, The role of prolactin in mammary carcinoma. Endocrine reviews 2003; 24(1):1-27

Panal M.D, Lan, Macdonld, The natural history of mammary carcinoma. Clin.Pathol. 2018;71:52-58.

Andrea D. Abati M.D, Marek Kimmel, Paul P. Rosan M D. Apocrine mammary carcinoma: A clinicopathologic study of 72 cases. American Journal of clinical Phathology, 1990;94(4):371-377.

S Luna-More, B Gonalez, C Acedo, I Rodrigo, Invasive micropillary carcinoma of the breast: a new special type of invasive mammary carcinoma, Research and Practice, 1994;190(7):668-674.

C Marques, J Correia, F Ferreira, A mammary carcinomas showed less aggressive clinicopathological features, contrasting with the cats that had triple negative carcinomas, 2016;8(8):1574 – 1575.

Elie Dagher, Jerome Abadie and Frederique, Feline Invasive Mammary Carcinomas: Prognostic Value of Histological Grading, 2019;56(5):7203.

Vuong D, Simpson PT, Green B, Cummings MC, Lakhani S R, Molecular classification of breast cancer. Virchows Arch 2014;465:1-14.

Rakha EA, Reis-Filho JS, Ellis IO, Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010;120:293-308.

Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC et al, The MPA mouse breast cancer model:evidence for a role of progesterone receptors in breast cancer. Endocr relat Cancer 2009;16:333-350.

Dickson RB, Johnson MD, Bano M, Shi E, Kurebayashi J, Ziff B, Martinez-Lacaci I, Amundadottir LT, Lippman ME, Growth factors in breast cancer: mitogenesis to transformation. J Steroid Biochem Mol Biol 1992;43:69–78

Love R.R, Rose D.R, Surawicz T.S, Newcomb P.A, Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer1991; 68:1401–1405

Kwa H.G, Wang D.Y, An abnormal luteal-phase evening peak of plasma prolactin in women with a family history of breast cancer. Int J Cancer 1977; 20:12–14

Musey V.C, Collins D.C, Musey P.I, Martino-Saltzman D, Preedy J.R, Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987;316:229–234

Wang D.Y, De Stavola B.L, Bulbrook R.D, Allen D.S, Kwa H.G, Verstraeten A.A, Moore J.W, Fentiman I.S, Hayward J.L, Gravelle I.H,The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 1988;24: 1225–1231

Ingram D.M, Nottage E.M, Roberts A.N, Prolactin and breast cancer risk. Med J Aust.1990;153:469–473

Hankinson S.E, Colditz G.A, Hunter D.J, Manson J.E, Willett W.C, Stampfer M.J, Longcope C, Speizer FE, Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses’ Health Study (United States). Cancer Causes Control 1995; 6:217–224

Apter D, Reinila M, Vihko R, Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 1989;44:783–787

Love R.R, Rose D.P, Elevated bioactive prolactin in women at risk for familial breast cancer. Eur J Cancer Clin Oncol 1985;21:1553–1554

Fishman J, Fukushima D, Connor J, Rosenfeld R.S, Lynch H.T, Lynch J.F, Guirgis H, Maloney K, Plasma hormone profiles of young women at risk for familial breast cancer. Cancer Res1978; 38: 4006–4011

Pike M.C, Casagrande J.T, Brown J.B, Gerkins V, Henderson B.E, Comparison of urinary and plasma hormone levels in daughters of breast cancer patients and controls. J Natl Cancer Inst 1977;59: 1351–1355

Boffard K, Clark G.M, Irvine J.B, Knyba R.E, Bulbrook R.D, Wang D.Y, Kwa H.G, Serum prolactin, androgens, oestradiol and progesterone in adolescent girls with or without a family history of breast cancer. Eur J Cancer Clin Oncol 1981;17:1071–1077

Wolfe J.N. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 1976;37:2486–2492

Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton L.A, Hoover R, Haile R. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622–1629

Boyd NF, Stone J, Martin L, Minkin S, Yaffe M, Sunnybrook and Women’s College Hospital, Mammographic densities and the growth hormone-IGF-1 prolactin axis. Proc 92nd Meeting of the American Association for Cancer Research, New Orleans, LA, 2001, p 558 (Abstract)

Byrne C, Hankinson SE, Colditz GA, Willett WC, Speizer FE, Channing Laboratory, Plasma prolactin and mammographic density in postmenopausal women. Proc 92nd Meeting of the American Association for Cancer Research, New Orleans, LA, 2001, p 153 (Abstract)

Gray G.E, Pike M.C, Hirayama T, Tellez J, Gerkins V, Brown J.B, Casagrande J.T, Henderson B.E, Diet and hormone profiles in teenage girls in four countries at different risk for breast cancer. Prev Med 1982;11:108–113

Rossing M.A, Scholes D, Cushing-Haugen K.L, Voigt L.F, Cimetidine use and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev2000; 9:319–323

Endogenous Hormones and Breast Cancer Collaborative Group, Endogenous sex hormones and breast cancer in postmenopausal women: collaborative reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–616

Strungs I, Gray R.A, Rigby H.B, Strutton G, Two case reports of breast carcinoma associated with prolactinoma. Pathology 1997;29: 320–323

Volm M.D, Talamonti M.S, Thangavelu M, Gradishar W.K, Pituitary adenoma and bilateral male breast cancer: an unusual association. J Surg Oncol 1997;64:74–78

Published
2024-09-13
How to Cite
Anusha Jasmin R J, Ramalingam Kothai, & Balasubramanian Arul. (2024). A Overview Of Type And New Emerging Preventive Measures Of Mammary Carcinoma: Mammary carcinoma. Revista Electronica De Veterinaria, 25(1), 1298 -1302. https://doi.org/10.69980/redvet.v25i1.856
Section
Articles